Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature
TEST_code
|
CME Activity Information |
|
Release Date: |
November 30, 2007 |
|
Most Recent Review: |
November 30, 2007* |
|
Most Recent Update: |
November 30, 2007 |
|
Date Credit Expires: |
November 30, 2009 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by November 30, 2009, in
order to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
in the field of Neuro-Oncology and are involved in providing patient care in a
cancer care environment.
Learning Objectives
After completing this course, the reader should be able to:
- Describe the clinical and radiologic manifestations of RPLS.
- Define agents or inciting risk factors that have been implicated in the
development of RPLS.
- Discuss the treatment and outcome of RPLS, emphasizing supportive care and
urgent discontinuation of the offending agent.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the School of Medicine
of The University of North Carolina at Chapel Hill and The Oncologist.
The School of Medicine of The University of North Carolina at Chapel Hill is accredited
by the ACCME to provide continuing medical education for physicians.
The School
of Medicine of The University of North Carolina at Chapel Hill designates this
educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the School
of Medicine of The University of North Carolina at Chapel Hill to ensure balance,
independence, objectivity, and scientific rigor in all of its educational activities
and to include information free of commercial bias and based on the best evidence
available. All individuals in a position to influence the content of this activity
have disclosed relevant financial interests or relationships of their own, their
spouse/partner, or their worksite, with manufacturers or providers of commercial
products, services, technology, or programs; and disclosed relationships with
current non-governmental supporters of the activity.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's
anonymous peer review process
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All final publication decisions are
made by the Editorial Board. The acceptance of a manuscript is based on its
originality and importance to the field as assessed by the Editors.
Content Review
The content of this manuscript has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.
Author Disclosure(s)
Anita Rajasekhar, M.D.
Credentials: Division of Hematology/Oncology, College of
Medicine, University of Florida, Gainesville, Florida, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Thomas J. George, Jr., M.D.
Credentials: Division of Hematology/Oncology, College of
Medicine, University of Florida, Gainesville, Florida, USA. Telephone:
352-273-7759; Fax: 352-392-8530; E-mail: thom.george{at}medicine.ufl.edu.
Disclosures: The author has indicated no relevant commercial
relationships.
Section Editors Disclosures
Tracy Batchelor, M.D., M.P.H., and Jean-Yves Delattre, M.D., have disclosed no financial relationships relevant to the content of this article.
CME Activity Director Disclosure
Frank M. Balis, M.D., CME Activity Director, Clinical Director, National Cancer Institute, has disclosed no financial relationships relevant to the content of this article.
Independent Peer Reviewers and Staff Managers Disclosures
No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or staff managers.
Commercial Support
Non-governmental supporters of this activity: Abraxis BioScience,
AstraZeneca, Bristol-Myers Squibb Oncology, Merck, Pfizer, and sanofi-aventis
Hardware/Software Requirements
The Oncologist CME Online supports
the following browsers: Current production versions of Opera, Safari, Firefox,
Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh
version of Explorer was discontinued in June 2003, and is not supported.
Other Links
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu
Copyright © 2008 by AlphaMed Press.